Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05620888
Recruiting Not applicable

Efficacy of a Tailored Communication Intervention Aimed At Increasing the Number of Daily Steps

NCT05620888 · tracked via the Priya Life Science Italy tracker
Phase
Not applicable
Started
2022-10-03
Last updated
2024-12-09

Condition(s) studied

Physical Inactivity

Investigational drug(s) / intervention(s)

Walk behavior change: Tailored messages (TM)Walk behavior change: Non tailored messages (NTM)

Walk behavior change: Tailored messages (TM): Every afternoon at the same time, the mobile application sends a message to the participants of the TM arm. The message is tailored based on the answers provided to the pre-intervention questionnaire. An example message is: "you think you are not able to walk regularly when your morale is low: do not give up because physical activity is also good for the mood!" The intervention is provided for 30 days.

Walk behavior change: Non tailored messages (NTM): Every afternoon at the same time, the mobile application sends a message to the participants of the NTM arm. The message concerns the emotional well-being resulting from the performance of the physical activity and is not tailored. An example message is: "walking regularly in the fresh air improves your mood." The intervention is provided for 30 days.

Study summary

This study aims to evaluate the efficacy of a physical activity promotion intervention focused on walking behavior. The intervention is delivered via mobile application in a sample drawn from the healthy adult population.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Participants from the general population, in good health and sedentary * A level of education sufficient to understand the procedures of the study and to use a smartphone * Having a smartphone Exclusion Criteria: * The participant always (or almost always) takes at least 7,000 steps a day * The participant achieves an IPAQ score equal to or greater than 3000 MET-min / week * The participant has symptoms or pathologies that could represent a contraindication to the physical activity proposed by the study. In particular * Cardiovascular diseases for which physical activity is allowed only under medical supervision * Chest pain during daily activities * Drug treatment for cardiovascular diseases * Severe arterial hypertension not pharmacologically controlled * Episodes of loss of consciousness within the past 12 months * Osteoarticular disorders that could be aggravated by a change in the level of physical activity * Fractures of the lower limbs, vertebrae, or pelvis in the past six months * Walking difficulty * Respiratory insufficiency

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Milano-Bicocca Milan MI Recruiting

More University of Milano Bicocca trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05620888 on ClinicalTrials.gov ↗ ← All trials in Italy